Fusion Antibodies plc
Status: Publicly traded
Direct answer
Fusion Antibodies plc is publicly traded on LSE under the ticker FAB.L.
Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses...
Can you invest in Fusion Antibodies plc?
Yes. Fusion Antibodies plc trades publicly on LSE as FAB.L.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Fusion Antibodies plc
Detailed equity research is provided by MarketSnap.